Extended Data Fig. 5: Survival analysis of our lung cancer cohort.
From: MHC II immunogenicity shapes the neoepitope landscape in human tumors
The samples of our lung cancer cohort (n = 335) were divided into high- and low- neoantigen load group, and the progression free survival of the two groups was compared. P values were generated from the Kaplan-Meier estimation.
